2. Clinical, cytogenetic and genomic profiling of B-Other Acute Lymphoblastic Leukemia: An Indian cohort study

∼30% of B-ALL patients remain unclassified at the genetic level, lacking known cytogenetic aberrations and are arbitrarily grouped intermediate risk, B-other-ALL. Recently, recurrent genetic abnormalities have emerged within this heterogeneous subgroup replacing the default assignment of intermedi ate risk with definitive prognostic information. We prospectively analyzed 368 patients to establish the incidence and complete clinical, cytogenetic and molecular profile of B-Other ALL in India. Fluorescence in situ hybridization (FISH) and Targeted RNA sequencing was carried out for detecting ph like ALL aberrations involving CRLF2, JAK2, EPOR, ABL1, ABL2, PDGFRB, CSF1R and IKZF1 and other known B-Other ALL abnormalities (IGH, DUX4, ZNF384, MEF2D, and PAX5).

Source: Cancer Genetics and Cytogenetics - November 1, 2022 Category: Genetics & Stem Cells Authors: Dhanlaxmi Shetty, Purvi Mohanty, Hemani Jain, Prashant Tembhare, Nikhil Patkar, Papagudi Subramanian, Jayashree Thorat, Lingaraj Nayak, Anant Gokarn, Sachin Punatar, Hasmukh Jain, Bhausaheb Bagal, Shyam Srinivasan, Akanksha Chichra, Nirmalya Roy, Chetan D Source Type: research